Volume 9 Supplement 1
Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells
- EJ Wehrens1Email author,
- G Mijnheer1,
- B Vastert1,
- M Klein1,
- J van Loosdregt1, 2,
- W de Jager1,
- PJ Coffer1, 2,
- BJ Prakken†1 and
- F van Wijk†1
© Wehrens et al; licensee BioMed Central Ltd. 2011
Published: 14 September 2011
During the last decade research has focused on the application of FOXP3+ regulatory T cells (Treg) in the treatment of autoimmune disease. However, thorough functional characterization of these cells in patients with chronic autoimmune disease, especially at the site of inflammation, is still missing.
Here we studied Treg function at the site of autoimmune inflammation in patients with juvenile idiopathic arthritis (JIA).
Mononuclear cells were isolated from peripheral blood (PB) of both patients and healthy controls (HC) and from synovial fluid of JIA patients. To study Treg function, in vitro suppression assays were performed measuring both T cell proliferation and cytokine production in the culture supernatant. In addition, responsiveness to TGFβ mediated suppression was investigated by culturing effector cells in the presence of TGFβ.
Treg from both the peripheral blood as well as the inflamed joints of JIA patients were fully functional. Nevertheless, Treg-mediated suppression of cell proliferation and cytokine production by effector cells from the site of inflammation was severely impaired, due to resistance to suppression. In these inflammatory effector cells, activation of protein kinase B (PKB)/c-akt was enhanced and inhibition of this kinase restored responsiveness to suppression.
PKB/c-akt hyperactivation causes resistance of effector cells to suppression at the site of inflammation in human autoimmune disease. These findings suggest that for a Treg enhancing strategy to be successful in the treatment of autoimmune inflammation, resistance of effector cells to suppression should be targeted as well. This might be achieved by selectively inhibiting PKB/c-akt activation.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.